Chris Raymond
Stock Analyst at Raymond James
(2.90)
# 1,424
Out of 5,242 analysts
9
Total ratings
66.67%
Success rate
46.64%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Chris Raymond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MNPR Monopar Therapeutics | Downgrades: Outperform | $142 → $123 | $64.95 | +89.38% | 3 | Nov 14, 2025 | |
| SION Sionna Therapeutics | Initiates: Strong Buy | $45 | $39.50 | +13.92% | 1 | Sep 3, 2025 | |
| TYRA Tyra Biosciences | Initiates: Strong Buy | $35 | $33.40 | +4.79% | 1 | Sep 3, 2025 | |
| NUVL Nuvalent | Initiates: Outperform | $105 | $102.32 | +2.62% | 1 | Sep 3, 2025 | |
| KLRS Kalaris Therapeutics | Initiates: Strong Buy | $23 | $4.83 | +376.19% | 1 | Sep 3, 2025 | |
| COGT Cogent Biosciences | Initiates: Strong Buy | $30 | $32.93 | -8.88% | 1 | Sep 3, 2025 | |
| BHVN Biohaven | Initiates: Strong Buy | $75 | $8.85 | +747.46% | 1 | Sep 3, 2025 |
Monopar Therapeutics
Nov 14, 2025
Downgrades: Outperform
Price Target: $142 → $123
Current: $64.95
Upside: +89.38%
Sionna Therapeutics
Sep 3, 2025
Initiates: Strong Buy
Price Target: $45
Current: $39.50
Upside: +13.92%
Tyra Biosciences
Sep 3, 2025
Initiates: Strong Buy
Price Target: $35
Current: $33.40
Upside: +4.79%
Nuvalent
Sep 3, 2025
Initiates: Outperform
Price Target: $105
Current: $102.32
Upside: +2.62%
Kalaris Therapeutics
Sep 3, 2025
Initiates: Strong Buy
Price Target: $23
Current: $4.83
Upside: +376.19%
Cogent Biosciences
Sep 3, 2025
Initiates: Strong Buy
Price Target: $30
Current: $32.93
Upside: -8.88%
Biohaven
Sep 3, 2025
Initiates: Strong Buy
Price Target: $75
Current: $8.85
Upside: +747.46%